Project Grant R01AI203609
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Indiana University (doing business as Indiana University) $617,374 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define nuclear pore complex subsets and import pathways that regulate HIV-1 integration and gene expression. The research will characterize how HIV-1 exploits nuclear pore complex remodeling and host factors to gain access to the nucleus in non-dividing cells,...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Indiana University $658,213 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how chronic viral infections suppress dendritic cell function and impair secondary immune responses. The research examines mechanisms by which persistent viral infections such as HIV and hepatitis B and C alter CD8 T cell priming through decreased dendritic cell activation. The...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Indiana University $710,142 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on CD4 TH1 cell restoration for control of chronic viral infections. The project, awarded as a Project Grant (R01AI190033), runs through August 31, 2031, with place of performance in Indianapolis, Indiana. The research addresses T cell exhaustion driven by prolonged...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Indiana University $1,595,769 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structural and functional research on HIV-1 Rev-response element (RRE) assembly and to develop inhibitors targeting the RRE-Rev complex. The funded work aims to determine the full-length RRE structure, test the sequential and cooperative mechanism of Rev protein assembly on the RRE, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $158,500 to Trustees of Indiana University (doing business as Indiana University Indianapolis) on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of a novel mouse model to analyze FOXP3+ T follicular helper (TFH) cells and their role in immune responses. The research addresses how follicular T regulatory...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $806,623 on May 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R56AI194947) to elucidate the structural and kinetic basis of HIV-1 broadly neutralizing antibody responses, focusing on transient states and intermediates in antibody-antigen interactions that govern affinity maturation and neutralization breadth. The funded research will employ structural and kinetic...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $790,946 to Indiana University Indianapolis on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate dysregulation of humoral immunity following Plasmodium infection. The research examines why Plasmodium infections fail to induce long-lasting antibody protection, unlike most other infections and vaccines. The project...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $161,868 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the mutational pathways and molecular mechanisms through which drug resistance evolves against latest-generation antiretroviral therapy drugs for HIV. The research combines three complementary approaches. First, the work uses Potts sequence-covariation fitness landscape models...
The National Institute of Allergy and Infectious Diseases awarded the Trustees of Indiana University $370,835 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a computational framework for analyzing HIV immune escape across viral diversity. The funded research addresses a critical gap in HIV immunology: the lack of a rigorous computational approach capable of distinguishing universal, robust escape mechanisms from noise caused by subtype-specific sampling and cohort bias. Current escape signatures often fail to generalize across HIV's genetic diversity, yielding fragmented, non-reproducible findings that resist translation into rational immunogen design or cure strategies. The project reframes HIV immune escape analysis as "generalization-first" science, treating robustness and uncertainty as primary scientific endpoints rather than post-hoc validation steps. Work proceeds through three aims. Aim 1 constructs a foundational computational substrate delivering interpretable, epitope-level representations of immune escape explicitly annotated with calibrated uncertainty diagnostics and cross-clade generalization benchmarks. Aim 2 establishes an in silico evolutionary laboratory, treating immune pressure as a manipulable engineering variable to map the "virtual resistance landscape," identify evolutionary tipping points, and distinguish dead-end targets from accessible escape routes. Aim 3 bridges the gap between molecular virology and population-level dynamics. Performance occurs at Woodbridge, Indiana, with a period of performance through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $370.8k | 8/18/26 |